Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2018 / Cilt: 28 - Sayı: 2

High Metabolic Tumor Volume and Total Lesion Glycolysis Derived from Baseline 18F-FDG PET/CT may Predict the Metabolic Abnormalities in Newly Diagnosed Cancer Patients

Başlangıç 18F-FDG PET/CT Temelli Yüksek Metabolik Tümör Volümü (MTV) ve Toplam Lezyon Glikoliz Değerleri Yeni Tanı Konulmuş Kanser Hastalarında Metabolik Bozuklukları Gösterebilir

Pages
69–78
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, MTV and TLG cut-off values determined by ROC analysis can predict metabolic abnormalities in initial BMR, LDH and albumin levels with high specificity and sensitivity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The present study was conducted to investigate the role of total body Metabolic Tumor Volume (MTV, mm3) and Total Lesion Glyco-lysis (TLG) values obtained by PET/CT imaging for predicting metabolic abnormalities in newly diagnosed cancer patients.
📊
Key Findings & Data:Initial metabolic status of patients was evaluated based on basal metabolic rates, serum vitamin, mineral, and biochemical metabolite levels and antioxidant enzyme capacities.
💡
Conclusion & Impact:In conclusion, MTV and TLG cut-off values determined by ROC analysis can predict metabolic abnormalities in initial BMR, LDH and albumin levels with high specificity and sensitivity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The present study was conducted to investigate the role of total body Metabolic Tumor Volume (MTV, mm3) and Total Lesion Glyco-lysis (TLG) values obtained by PET/CT imaging for predicting metabolic abnormalities in newly diagnosed cancer patients. Patients having solid tumors with initial PET/CT staging were evaluated in a prospective cohort study. MTV and TLG values of all patients were measured besides SUV values as PET/CT parameters. Initial metabolic status of patients was evaluated based on basal metabolic rates, serum vitamin, mineral, and biochemical metabolite levels and antioxidant enzyme capacities. The MTV and TLG levels revealed significant relationships with cancer-induced metabolic abnormalities as high BMR and LDH, and low albumin levels as well as ad-vanced stage and presence of metastasis (p 20 Kcal/kg) were obtained to be > 52400 mm3 for MTV (0.84 and 0.63) and >274208 for TLG (0.84 and 0.63). The same values for high LDH were ≥ 219520 mm3 (0.52 and 0.88) for MTV and ≥ 411792 (0.78 and 0.58) for TLG, respectively. The values for low albumin levels were ≥89520 mm3 (0.63 and 0.10) for MTV, and ≥ 887840 (0.75 and 1.00 ) for TLG, respectively. In conclusion, MTV and TLG cut-off values determined by ROC analysis can predict metabolic abnormalities in initial BMR, LDH and albumin levels with high specificity and sensitivity. It is recommended to test MTV and TLG levels to determine initial metabolic status of diverse patient groups with various types of cancer.

Özet

Bu çalışma PET/CT’den elde edilen tüm vücut Metabolik Tümör Volümü (MTV, mm3) ve Toplam Lezyon Glikoliz (TLG) değerlerinin kans-er hastalarında metabolik bozuklukları tahmin etmedeki rolünü araştırmak için yapıldı. Prospektif kohort çalışmada başlangıç PET/CT evrelemesi yapılan yeni tanı konmuş solid tümör hastaları değerlendirildi. Tüm hastalarda PET/CT parametresi olarak SUV değerlerinin yanında MTV ve TLG değerleri de ölçüldü. Hastaların başlangıç metabolik durumu bazal metabolizma hızları, serum vitamin, mineral ve biyokimyasal metabolit düzeyleri ve antioksidan enzim kapasiteleri ile değerlendirildi. MTV ve TLG değerleri ileri evre hastalık ve metastaz varlığının yanı sıra artmış BMR, yüksek LDH ve düşük albümin değerleri gibi kanserin yol açtığı metabolik bozukluklar ile anlamlı ilişki gösterdi (p< 0.05).

🔖

Cite This Article

GUNDOGAN, K., KAYNAR, L., ABDULREZZAK, U., CETİN, M., AKKURT, S., YILMAZ, S., INANC, M., YILDIZHAN, E., KULA, M., ZARARSIZ, G., UCAR, M., TURAK, E. E., OZASLAN, E., CETIN, A. (2022). High Metabolic Tumor Volume and Total Lesion Glycolysis Derived from Baseline 18F-FDG PET/CT may Predict the Metabolic Abnormalities in Newly Diagnosed Cancer Patients. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 28 - Sayı: 2, 69–78. https://ajindex.com/articles/644781

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Badjatia N, Satyam A, Singh P, et al. Altered antioxidant sta-tus and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol Semin Orig Investig 28: 360- 367, 2010.
  2. Sharma M, Rajappa M, Kumar G, Sharma A. Oxidant-anti-oxidant status in Indian patients with carcinoma of posterior one-third of tongue. Cancer Biomarkers 5: 253-260, 2009. Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition 29: 15-21, 2013. Bozzetti F. Nutritional support of the oncology patient. Crit Rev Oncol Hematol 87: 172-200, 2013.
  3. Caccialanza R, Pedrazzoli P, Cereda E, et al. Nutritional sup-port in cancer patients: A position paper from the Italian so-ciety of medical oncology (AIOM) and the Italian society of artificial nutrition and metabolism (SINPE). J Cancer 7: 131- 135, 2016.
  4. Liu X, Meng QH, Ye Y, et al. Prognostic significance of pre-treatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic breast cancer. Carcinogenesis 36: 243-248, 2014.
  5. Yeun JY, Kaysen G. Factors influencing serum albumin in di-alysis patients. Am J Kidney Dis 32: S118-25, 1998
  6. Agrawal A, Gandhe MB, Gupta D, Reddy MVR. Preliminary study on serum lactate dehydrogenase (LDH)-prognostic bio-marker in carcinoma breast. J Clin Diagn Res 10: BC06-8,2016.
  7. Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lac-tate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol (Madr) 54: 961-970,2015.
  8. Liu R, Cao J, Gao X, et al. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L. Tumor Biol 37: 14083-14088, 2016.
  9. Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol 867: 115-224, 2015.
  10. Nguyen TYV, Batterham MJ, Edwards C. Comparison of rest-ing energy expenditure between cancer subjects and healthy controls: A meta-analysis. Nutr Cancer 68: 374-387, 2016.
  11. Cao D xing, Wu G hao, Zhang B, et al. Resting energy ex-penditure and body composition in patients with newly de-tected cancer. Clin Nutr 29: 72-77, 2010.
  12. Son SH, Lee SW, Jeong SY, et al. Whole-body metabolic tumor volume, as determined by 18F-FDG PET/CT, as a prognostic factor of outcome for patients with breast cancer who have distant metastasis. Am J Roentgenol 205: 878- 885, 2015.
  13. Marinelli B, Espinet-Col C, Ulaner GA, et al. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastat-ic triple negative breast cancer patien